



Technical Bulletin

Discontinuation of Abbott SARS-CoV-2 (COVID-19) IgG, Qualitative Nucleocapsid Assay

TO: Medical Staff and Clients

FROM: Dr. Wesley Kim, MD
Medical Director, DLS and QMC West

Dr. A. Christian Whelen, PhD Dr. Ana Ortega-Lopez, MD
VP & Technical Director Medical Director QMC Punchbowl,
Microbiology & Molecular North Hawaii and Molokai

DATE: April 12, 2021

SUBJECT: Discontinuation of Serology Tests for Abbott SARS-CoV-2 (COVID-19) IgG, Qualitative Nucleocapsid assay at DLS (Order Code 7202)

Beginning April 15, 2021, Diagnostic Laboratory Services will no longer offer the Abbott SARS-CoV-2 (COVID-19) IgG, Qualitative Nucleocapsid assay (Order Code 7202) because it is essentially redundant to our preferred method, Roche SARS-CoV-2 NucleoCapsid Total Antibody, Qualitative (Order Code 7203) [[FDA EUA-approved tests for SARS-CoV-2 \(COVID-19\) available at DLS includes total antibody \(dlslab.com\)](#)]. It was the first reputable assay to market [[Serology Tests for SARS-CoV-2 \(COVID-19\) Now Available \(dlslab.com\)](#)], so we secured test kits. The remaining kits will expire soon, and will not be replaced.

DLS will continue to offer:

- 1) ROCHE SARS-CoV-2 Nucleocapsid Total Antibody, Qualitative (Order Code 7203)
- 2) ROCHE SARS-CoV-2 Spike Total Antibody, Semi-Quantitative (Order Code 7681)

In patients who were infected with COVID-19, it is expected that antibodies to both the Nucleocapsid and Spike Protein antigen will be present. However, in patients who are only immunized with current vaccines on the market, they will only show antibodies to the Spike Protein antigen and NOT the nucleocapsid antigen.

If you have any questions please call DLS Client Services at 589-5101, Jantzen Lim, Core Lab Manager at 589-5265, Dr Wesley Kim at 589-5131, or Dr Chris Whelen at 589-5242.